메뉴 건너뛰기




Volumn 85, Issue 3, 2000, Pages 298-303

Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients

Author keywords

C4; predictors; Eosinophils; Immunologic parameters; Immunotherapy

Indexed keywords

RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2;

EID: 0034085042     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (20)

References (46)
  • 1
    • 0030272248 scopus 로고    scopus 로고
    • Interleukin 2 and its receptors: Recent advances and new immunological functions
    • Theze J, Alzari PM, Bertoglio J. Interleukin 2 and its receptors: recent advances and new immunological functions. Immunol Today 1996; 17:481-6.
    • (1996) Immunol Today , vol.17 , pp. 481-486
    • Theze, J.1    Alzari, P.M.2    Bertoglio, J.3
  • 2
    • 0343464573 scopus 로고    scopus 로고
    • Inhibition of non-hemopoietic cancer cell growth by interleukin-4 and related cytokines
    • Dalgleish AG, Browning M, eds. Cambridge: University Press
    • Hoon DSB, Morisaki T, Essner R. Inhibition of non-hemopoietic cancer cell growth by interleukin-4 and related cytokines. In: Dalgleish AG, Browning M, eds. Tumor immunology. Immunotherapy and cancer vaccines. Cambridge: University Press; 1996. p. 219-40.
    • (1996) Tumor Immunology. Immunotherapy and Cancer Vaccines , pp. 219-240
    • Hoon, D.S.B.1    Morisaki, T.2    Essner, R.3
  • 3
    • 0028304484 scopus 로고
    • In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2
    • Schwartzentruber DJ, Hom SS, Dadmarz R, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994; 12:1475-83.
    • (1994) J Clin Oncol , vol.12 , pp. 1475-1483
    • Schwartzentruber, D.J.1    Hom, S.S.2    Dadmarz, R.3
  • 4
    • 0027980190 scopus 로고
    • Interleukin-2: Solid-tumor therapy
    • Oppenheimer MH, Lotze MT. Interleukin-2: solid-tumor therapy. Oncology 1994; 51:154-69.
    • (1994) Oncology , vol.51 , pp. 154-169
    • Oppenheimer, M.H.1    Lotze, M.T.2
  • 5
    • 0026485322 scopus 로고
    • Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ
    • Weidmann E, Sacchi M, Plaisance S, et al. Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ. Cancer Res 1992; 52: 5963-70.
    • (1992) Cancer Res , vol.52 , pp. 5963-5970
    • Weidmann, E.1    Sacchi, M.2    Plaisance, S.3
  • 6
    • 0031914321 scopus 로고    scopus 로고
    • Cancer-associated muc1 mucin inhibits human t-cell proliferation, which is reversible by il-2
    • Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 1998; 4:43-9.
    • (1998) Nat Med , vol.4 , pp. 43-49
    • Agrawal, B.1    Krantz, M.J.2    Reddish, M.A.3    Longenecker, B.M.4
  • 7
    • 0026348767 scopus 로고
    • Cytokine regulation of eosinophil function
    • Weller PF. Cytokine regulation of eosinophil function. Clin Immunol Immunop 1992; 62:S55-9.
    • (1992) Clin Immunol Immunop , vol.62
    • Weller, P.F.1
  • 8
    • 0023115642 scopus 로고
    • A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
    • Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316:889-97.
    • (1987) N Engl J Med , vol.316 , pp. 889-897
    • Rosenberg, S.A.1    Lotze, M.T.2    Muul, L.M.3
  • 9
    • 0023123517 scopus 로고
    • Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
    • West WH, Tauer KW, Yannelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898-905.
    • (1987) N Engl J Med , vol.316 , pp. 898-905
    • West, W.H.1    Tauer, K.W.2    Yannelli, J.R.3
  • 10
    • 0025330178 scopus 로고
    • Home therapy with recombinant interleukin-2 and interferon-α 2b in advanced human malignancies
    • Atzpodien J, Körfer A, Franks CR, Poliwoda H, Kirchner H. Home therapy with recombinant interleukin-2 and interferon-α 2b in advanced human malignancies. Lancet 1990; 335:1509-12.
    • (1990) Lancet , vol.335 , pp. 1509-1512
    • Atzpodien, J.1    Körfer, A.2    Franks, C.R.3    Poliwoda, H.4    Kirchner, H.5
  • 11
    • 0030798858 scopus 로고    scopus 로고
    • Effectiveness of very low doses of immunotherapy in advanced renal cell cancer
    • Buzio C, De Palma G, Passalacqua R, et al. Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br J Cancer 1997; 76:541-4.
    • (1997) Br J Cancer , vol.76 , pp. 541-544
    • Buzio, C.1    De Palma, G.2    Passalacqua, R.3
  • 12
    • 0031572573 scopus 로고    scopus 로고
    • Nitrate plasma level as a marker of nitric oxide production after subcutaneous interleukin-2 immunotherapy
    • Porta C, Moroni M, Bobbio-Pallavicini E, Tinelli C, Regazzi-Bonora M. Nitrate plasma level as a marker of nitric oxide production after subcutaneous interleukin-2 immunotherapy. J Natl Cancer Inst 1997; 89:1545.
    • (1997) J Natl Cancer Inst , vol.89 , pp. 1545
    • Porta, C.1    Moroni, M.2    Bobbio-Pallavicini, E.3    Tinelli, C.4    Regazzi-Bonora, M.5
  • 13
    • 0026663801 scopus 로고
    • Tumor-associated eosinophilia in interleukin-2-treated patients: Evidence of toxic eosinophil degranulation on bladder cancer cells
    • Huland E, Huland H. Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. J Cancer Res Clin 1992; 118:463-7.
    • (1992) J Cancer Res Clin , vol.118 , pp. 463-467
    • Huland, E.1    Huland, H.2
  • 14
    • 0027298415 scopus 로고
    • In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5
    • Rivoltini L, Viggiano V, Spinazzè, et al. In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Int J Cancer 1993; 54:8-15.
    • (1993) Int J Cancer , vol.54 , pp. 8-15
    • Rivoltini, L.1    Viggiano, V.2
  • 15
    • 0031574104 scopus 로고    scopus 로고
    • Cationic protein-rich supernatants of cultured eosinophils from IL-2-treated patients have no cytotoxic activity on human renal cell carcinoma and melanoma cells: A preliminary report
    • Moroni M, Porta C, Gritti D, et al. Cationic protein-rich supernatants of cultured eosinophils from IL-2-treated patients have no cytotoxic activity on human renal cell carcinoma and melanoma cells: a preliminary report. Ann NY Acad Sci 1997; 832:295-303.
    • (1997) Ann NY Acad Sci , vol.832 , pp. 295-303
    • Moroni, M.1    Porta, C.2    Gritti, D.3
  • 16
    • 0026786510 scopus 로고
    • Correlation ofeosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C
    • Arinaga S, Karimine N, Takamuku K, et al. Correlation ofeosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C. Cancer Immunol Immun 1992; 35:246-50.
    • (1992) Cancer Immunol Immun , vol.35 , pp. 246-250
    • Arinaga, S.1    Karimine, N.2    Takamuku, K.3
  • 17
    • 0020349687 scopus 로고
    • Influence of macrophage activation on the synthesis of complement components C2, C3, C4
    • Hartung HP, Zanker B, Bitter-Suermann D. Influence of macrophage activation on the synthesis of complement components C2, C3, C4. Adv Exp Med Biol 1982; 155:525-9.
    • (1982) Adv Exp Med Biol , vol.155 , pp. 525-529
    • Hartung, H.P.1    Zanker, B.2    Bitter-Suermann, D.3
  • 18
    • 0028913615 scopus 로고
    • Benign idiopathic hypereosinophilia: A feeble masquerader or a smouldering form of the hypereosinophilic syndrome?
    • Confalonieri M, Tacconi F, De Amici M, et al. Benign idiopathic hypereosinophilia: a feeble masquerader or a smouldering form of the hypereosinophilic syndrome? Haematologica 1995; 80:50-3.
    • (1995) Haematologica , vol.80 , pp. 50-53
    • Confalonieri, M.1    Tacconi, F.2    De Amici, M.3
  • 19
    • 0003486931 scopus 로고
    • Offset publication 48. Geneva, World Health Organization
    • World Health Organization. WHO Handbook for reporting results of cancer treatment. Offset publication 48. Geneva, World Health Organization, 1979.
    • (1979) Who Handbook for Reporting Results of Cancer Treatment
  • 21
    • 0026442546 scopus 로고
    • Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer
    • Fiorentino B, Di Stefano P, Giuliani C, et al. Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer. Br J Cancer 1992; 66:981-3.
    • (1992) Br J Cancer , vol.66 , pp. 981-983
    • Fiorentino, B.1    Di Stefano, P.2    Giuliani, C.3
  • 22
    • 0026500134 scopus 로고
    • Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: Clinical results and immunological effects
    • Hermann GG, Geertsen PF, von der Maase H, et al. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects. Cancer Res 1992; 52:726-33.
    • (1992) Cancer Res , vol.52 , pp. 726-733
    • Hermann, G.G.1    Geertsen, P.F.2    Von Der Maase, H.3
  • 23
    • 0027399765 scopus 로고
    • Low-dose interleukin-2 in combination with interferon-α effectively modulates biological response in vivo
    • Schneekloth H, Korfer A, Hadam M, et al. Low-dose interleukin-2 in combination with interferon-α effectively modulates biological response in vivo. Acta Haematol 1993; 89:13-21.
    • (1993) Acta Haematol , vol.89 , pp. 13-21
    • Schneekloth, H.1    Korfer, A.2    Hadam, M.3
  • 24
    • 0027450783 scopus 로고
    • A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans
    • Schiller JH, Hank J, Storer B, et al. A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans. Cancer Res 1993; 53:1286-92.
    • (1993) Cancer Res , vol.53 , pp. 1286-1292
    • Schiller, J.H.1    Hank, J.2    Storer, B.3
  • 25
    • 0029595269 scopus 로고
    • High-dose continuous venous infusion of interleukin-2: Influence of dose and infusion rate on tumoricidal function and lymphocyte subsets
    • Mertens WC, Banerjee D, al-Mutter N, Stitt L, Bramwell VH, Lala PK. High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsets. Cancer Immunol Immun 1995; 41:271-9.
    • (1995) Cancer Immunol Immun , vol.41 , pp. 271-279
    • Mertens, W.C.1    Banerjee, D.2    Al-Mutter, N.3    Stitt, L.4    Bramwell, V.H.5    Lala, P.K.6
  • 27
    • 0030915612 scopus 로고    scopus 로고
    • Cancer dormancy: Opportunities for new therapeutic approaches
    • Uhr JW, Scheuermann RH, Street NE, Vitetta ES. Cancer dormancy: opportunities for new therapeutic approaches. Nat Med 1997; 3:505-9.
    • (1997) Nat Med , vol.3 , pp. 505-509
    • Uhr, J.W.1    Scheuermann, R.H.2    Street, N.E.3    Vitetta, E.S.4
  • 29
    • 0022474118 scopus 로고
    • Tumor dormancy. I. Regression of BCL1 tumor and induction of a dormant tumor state in mice chimeric at the major histocompatibility complex
    • Siu H, Vitetta ES, May RD, Uhr JW. Tumor dormancy. I. Regression of BCL1 tumor and induction of a dormant tumor state in mice chimeric at the major histocompatibility complex. J Immunol 1986; 137:1376-82.
    • (1986) J Immunol , vol.137 , pp. 1376-1382
    • Siu, H.1    Vitetta, E.S.2    May, R.D.3    Uhr, J.W.4
  • 30
    • 0020646433 scopus 로고
    • Suppression and elimination of BCL1 leukemia byallogeneic bone marrow transplantation
    • Weiss L, Morecki S, Vitetta ES, Slavin S. Suppression and elimination of BCL1 leukemia byallogeneic bone marrow transplantation. J Immunol 1983; 130:2452-5.
    • (1983) J Immunol , vol.130 , pp. 2452-2455
    • Weiss, L.1    Morecki, S.2    Vitetta, E.S.3    Slavin, S.4
  • 32
    • 0028018095 scopus 로고
    • Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection
    • Khazaie K, Prifti S, Beckhove P, et al. Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. Proc Natl Acad Sci USA 1994; 91:7430-4.
    • (1994) Proc Natl Acad Sci USA , vol.91 , pp. 7430-7434
    • Khazaie, K.1    Prifti, S.2    Beckhove, P.3
  • 33
    • 0342594637 scopus 로고    scopus 로고
    • The immunosurveillance of cancer: Specific and nonspecific mechanisms
    • Dalgleish AG, Browning M, eds. Cambridge: University Press
    • Vile RG, Chong H, Dorudi S. The immunosurveillance of cancer: specific and nonspecific mechanisms. In: Dalgleish AG, Browning M, eds. Tumor immunology. Immunotherapy and cancer vaccines. Cambridge: University Press; 1996. p. 7-38.
    • (1996) Tumor Immunology. Immunotherapy and Cancer Vaccines , pp. 7-38
    • Vile, R.G.1    Chong, H.2    Dorudi, S.3
  • 34
    • 0025916290 scopus 로고
    • Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2
    • Lissoni P, Tisi E, Brivio F, et al. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2. Eur J Cancer 1991; 27:1014-6.
    • (1991) Eur J Cancer , vol.27 , pp. 1014-1016
    • Lissoni, P.1    Tisi, E.2    Brivio, F.3
  • 35
    • 0027270598 scopus 로고
    • Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: Preliminary results
    • Lissoni P, Barni S, Rovelli F, et al. Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results. Eur J Cancer 1993; 29A: 185-9.
    • (1993) Eur J Cancer , vol.29 A , pp. 185-189
    • Lissoni, P.1    Barni, S.2    Rovelli, F.3
  • 37
    • 0027494385 scopus 로고
    • Action of natural killer cells and macrophages in cancer
    • Klein E, Mantovani A. Action of natural killer cells and macrophages in cancer. Curr Opin Immunol 1993; 5: 714-8.
    • (1993) Curr Opin Immunol , vol.5 , pp. 714-718
    • Klein, E.1    Mantovani, A.2
  • 38
    • 0028132648 scopus 로고
    • Alveolar macrophage inhibition of lung-associated NK activity: Involvement of prostaglandins and transforming growth factor-beta 1
    • Lauzon W, Lemaire I. Alveolar macrophage inhibition of lung-associated NK activity: involvement of prostaglandins and transforming growth factor-beta 1. Exp Lung Res 1994; 20:331-49.
    • (1994) Exp Lung Res , vol.20 , pp. 331-349
    • Lauzon, W.1    Lemaire, I.2
  • 39
    • 0029835231 scopus 로고    scopus 로고
    • The role of tumor necrosis factor (TNF) family members in IL-2 toxicity and tumor regression
    • Mier J, Lawrence D, Unrau M, Atkins M. The role of tumor necrosis factor (TNF) family members in IL-2 toxicity and tumor regression. Int J Immunopathol 1996; 2:39-42.
    • (1996) Int J Immunopathol , vol.2 , pp. 39-42
    • Mier, J.1    Lawrence, D.2    Unrau, M.3    Atkins, M.4
  • 40
    • 0029840585 scopus 로고    scopus 로고
    • Fas ligand and immune evasion
    • Nagata S. Fas ligand and immune evasion. Nat Med 1996; 2:1306-7.
    • (1996) Nat Med , vol.2 , pp. 1306-1307
    • Nagata, S.1
  • 41
    • 0026754550 scopus 로고
    • Tumor-associated tissue inflammatory reaction and eosinophilia in primary superficial bladder cancer
    • Flamm J. Tumor-associated tissue inflammatory reaction and eosinophilia in primary superficial bladder cancer. Urology 1992; 40:180-5.
    • (1992) Urology , vol.40 , pp. 180-185
    • Flamm, J.1
  • 42
    • 0027970322 scopus 로고
    • Tumor-associated tissue eosinophilia and long-term prognosis for carcinoma of the larynx
    • Thompson AC, Bradley PJ, Griffin NR. Tumor-associated tissue eosinophilia and long-term prognosis for carcinoma of the larynx. Am J Surg 1994; 168:469-71.
    • (1994) Am J Surg , vol.168 , pp. 469-471
    • Thompson, A.C.1    Bradley, P.J.2    Griffin, N.R.3
  • 43
    • 0030024150 scopus 로고    scopus 로고
    • Prevalence and prognostic significance of tumor-associated tissue eosinophilia in nasopharyngeal carcinoma
    • Leighton SE, Teo JG, Leung SF, Cheung AY, Lee JC, van-Hasselt CA. Prevalence and prognostic significance of tumor-associated tissue eosinophilia in nasopharyngeal carcinoma. Cancer 1996; 77:436-40.
    • (1996) Cancer , vol.77 , pp. 436-440
    • Leighton, S.E.1    Teo, J.G.2    Leung, S.F.3    Cheung, A.Y.4    Lee, J.C.5    Van-Hasselt, C.A.6
  • 44
    • 0030837554 scopus 로고    scopus 로고
    • Eosinophils and human cancer
    • Samoszuk M. Eosinophils and human cancer. Histol Histopathol 1997; 12:807-12.
    • (1997) Histol Histopathol , vol.12 , pp. 807-812
    • Samoszuk, M.1
  • 45
    • 0030765161 scopus 로고    scopus 로고
    • The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer
    • Trulson A, Nilsson S, Venge P. The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer. Br J Haematol 1997; 98:312-4.
    • (1997) Br J Haematol , vol.98 , pp. 312-314
    • Trulson, A.1    Nilsson, S.2    Venge, P.3
  • 46
    • 0031864807 scopus 로고    scopus 로고
    • Eosinophils and serum eosinophilic cationic proteins in interleukin-2-based immunotherapy for cancer
    • Porta C, Moroni M, De Amici M. Eosinophils and serum eosinophilic cationic proteins in interleukin-2-based immunotherapy for cancer. Br J Haematol 1998; 100:607-9.
    • (1998) Br J Haematol , vol.100 , pp. 607-609
    • Porta, C.1    Moroni, M.2    De Amici, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.